Clostridium difficile phages: still difficult?
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Phages that infect Clostridium difficile were first isolated for typing purposes in the 1980s, but their use was short lived. However, the rise of C. difficile epidemics over the last decade has triggered a resurgence of interest in using phages to combat this pathogen. Phage therapy is an attractive treatment option for C. difficile infection, however, developing suitable phages is challenging. In this review we summarize the difficulties faced by researchers in this field, and we discuss the solutions and strategies used for the development of C. difficile phages for use as novel therapeutics. Epidemiological data has highlighted the diversity and distribution of C. difficile, and shown that novel strains continue to emerge in clinical settings. In parallel with epidemiological studies, advances in molecular biology have bolstered our understanding of C. difficile biology, and our knowledge of phage-host interactions in other bacterial species. These three fields of biology have therefore paved the way for future work on C. difficile phages to progress and develop. Benefits of using C. difficile phages as therapeutic agents include the fact that they have highly specific interactions with their bacterial hosts. Studies also show that they can reduce bacterial numbers in both in vitro and in vivo systems. Genetic analysis has revealed the genomic diversity among these phages and provided an insight into their taxonomy and evolution. No strictly virulent C. difficile phages have been reported and this contributes to the difficulties with their therapeutic exploitation. Although treatment approaches using the phage-encoded endolysin protein have been explored, the benefits of using "whole-phages" are such that they remain a major research focus. Whilst we don't envisage working with C. difficile phages will be problem-free, sufficient study should inform future strategies to facilitate their development to combat this problematic pathogen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Flemming, H.-C., & Wingender, J. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2415 · Cited by 10,137
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Clostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380 · cited 2×
“…form of RNA based adaptive bacterial immunity to foreign DNA, Clostridium difficile infection is generally associated with the production of up to three toxins; toxin A and toxin B, which are encoded on a pathogenicity locus; the PaLoc, and the C. difficile binary toxin (CDT; Rupnik et al., 2009).”
BackgroundInfluentialThe ClosTron: a universal gene knock-out system for the genus Clostridium
Heap, J. T., Pennington, O. J., Cartman, S. T., Carter, G. P., & Minton, N. P. (2007) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2007.05.021 · Cited by 663
Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome
Modi, S. R., Lee, H. H., Spina, C. S., & Collins, J. J. (2013) · Nature · doi:10.1038/nature12212 · Cited by 542
Rea, M. C., Dobson, A., O'Sullivan, O., Crispie, F., Fouhy, F., Cotter, P. D., Shanahan, F., Kiely, B., Hill, C., & Ross, R. P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001224107 · Cited by 377
Purdy, D., O'Keeffe, T. A. T., Elmore, M., Herbert, M., McLeod, A., Bokori‐Brown, M., Ostrowski, A., & Minton, N. P. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03134.x · Cited by 255
Cited by
Phage Therapy in the Postantibiotic Era
Gordillo Altamirano, F. L., & Barr, J. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00066-18 · Cited by 1,180
Clostridium difficile infection
Smits, W. K., Lyras, D., Lacy, D. B., Wilcox, M. H., & Kuijper, E. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.20 · Cited by 853
Bacteriophages of the Human Gut: The “Known Unknown” of the Microbiome
Shkoporov, A. N., & Hill, C. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.01.017 · Cited by 767
Current challenges and future opportunities of phage therapy
Pires, D. P., Costa, A. R., Pinto, G., Meneses, L., & Azeredo, J. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa017 · Cited by 340
Revisiting phage therapy: new applications for old resources
Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.01.006 · Cited by 310
Metadata
- Authors
- Hargreaves, K. R., & Clokie, M. R. J.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2014-04-28
- Volume
- 5
- Pages
- 184-184
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W2012427120
- Cited by
- 125
- References
- 7
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clostridium difficile phages: still difficult? https://app.cochat.ai/papers/10.3389/fmicb.2014.00184
- The paper
- Hargreaves, K. R., & Clokie, M. R. J. (2014). Clostridium difficile phages: still difficult? Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2014.00184
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.